Impact of Neurointensivist Co-Management in a Semiclosed Neurocritical-Care Unit
10.3988/jcn.2020.16.4.681
- Author:
Sang Hwa KIM
1
;
Kyu Sun YUM
;
Jin-Heon JEONG
;
Jae Hyung CHOI
;
Hyun-Seok PARK
;
Young Jin SONG
;
Dae-Hyun KIM
;
Jae-Kwan CHA
;
Moon-Ku HAN
Author Information
1. Departments of Neurosurgery, Dong-A University Hospital, Dong-A University College of Medicine, Busan, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Journal of Clinical Neurology
2020;16(4):681-687
- CountryRepublic of Korea
- Language:0
-
Abstract:
Background:and Purpose: The importance of the specialized management of neurocritical patients is being increasingly recognized. We evaluated the impact of neurointensivist comanagement on the clinical outcomes (particularly the mortality rate) of neurocritical patients admitted to a semiclosed neurocritical-care unit (NCU).
Methods:We retrospectively included neurocritical patients admitted to the NCU between March 2015 and February 2018. We analyzed the clinical data and compared the outcomes between patients admitted before and after the initiation of neurointensivist co-management in March 2016.
Results:There were 1,785 patients admitted to the NCU during the study period. Patients younger than 18 years (n=28) or discharged within 48 hours (n=200) were excluded. The 1,557 remaining patients comprised 590 and 967 who were admitted to the NCU before and after the initiation of co-management, respectively. Patients admitted under neurointensivist co-management were older and had higher Acute Physiologic Assessment and Chronic Health Evaluation II scores. The 30-day mortality rate was significantly lower after neurointensivist co-management (p=0.042). A multivariate logistic regression analysis demonstrated that neurointensivist co-management significantly reduced mortality rates in the NCU and in the hospital overall [odds ratio=0.590 (p=0.002) and 0.585 (p=0.001), respectively].
Conclusions:Despite the higher severity of the condition during neurointensivist co-management, co-management significantly improved clinical outcomes (including the mortality rate) in neurocritical patients.
